OptimizeRx Co. (NASDAQ:OPRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of OptimizeRx Co. (NASDAQ:OPRX) have received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $16.00.

A number of brokerages have weighed in on OPRX. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price objective on shares of OptimizeRx in a report on Monday, April 1st. Stifel Nicolaus reaffirmed a “buy” rating and issued a $13.00 price objective on shares of OptimizeRx in a report on Wednesday, May 15th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of OptimizeRx in a report on Friday, June 21st.

Institutional Investors Weigh In On OptimizeRx

Several institutional investors have recently modified their holdings of OPRX. First Light Asset Management LLC lifted its stake in OptimizeRx by 0.6% in the 1st quarter. First Light Asset Management LLC now owns 1,737,584 shares of the company’s stock valued at $21,112,000 after buying an additional 10,286 shares in the last quarter. Vanguard Group Inc. lifted its stake in OptimizeRx by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,027,293 shares of the company’s stock valued at $12,482,000 after buying an additional 6,291 shares in the last quarter. AWM Investment Company Inc. lifted its stake in OptimizeRx by 4.0% in the 1st quarter. AWM Investment Company Inc. now owns 853,042 shares of the company’s stock valued at $10,364,000 after buying an additional 33,000 shares in the last quarter. Blair William & Co. IL lifted its stake in OptimizeRx by 5.6% in the 1st quarter. Blair William & Co. IL now owns 782,573 shares of the company’s stock valued at $9,508,000 after buying an additional 41,469 shares in the last quarter. Finally, Kennedy Capital Management LLC purchased a new stake in OptimizeRx in the 3rd quarter valued at approximately $4,323,000. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Trading Up 0.8 %

NASDAQ OPRX opened at $10.07 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.88 and a quick ratio of 2.88. OptimizeRx has a 52-week low of $6.92 and a 52-week high of $16.65. The business’s 50-day moving average price is $11.15 and its 200 day moving average price is $12.78.

OptimizeRx (NASDAQ:OPRX) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). OptimizeRx had a negative return on equity of 6.96% and a negative net margin of 23.10%. The company had revenue of $19.69 million for the quarter, compared to analysts’ expectations of $18.66 million. During the same period in the prior year, the business earned ($0.34) EPS. On average, sell-side analysts predict that OptimizeRx will post -0.42 earnings per share for the current year.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.